曲妥珠单抗及多西他赛联合护理干预治疗转移性乳腺癌HER-2强表达患者75例

Docetaxel and Herceptin Combined with Nursing Intervention in Treating Metastatic Breast Cancer HER- 2 Strong Expression in 75 Cases

目的探讨转移性乳腺癌HER-2强表达患者采用曲妥珠单抗及多西他赛治疗联合护理的临床效果。方法将2011年3月至2014年5月收治的150例转移性乳腺癌HER-2强表达患者按随机数字表法分为研究组和对照组,各75例。对照组患者仅使用曲妥珠单抗及多西他赛药物治疗,研究组患者在对照组基础上联合护理干预措施。结果研究组患者接受3个月的治疗后发热、皮疹、骨髓抑制、胃肠道不适等不良反应发生率均低于对照组(χ2=7.2921,P=0.006 9<0.05);两组患者治疗3个月后的卡氏生活质量评分(KPS)和生活质量评定量表评分(QOL)显著高于治疗前(P<0.05),且研究组评分显著高于对照组(P<0.05);治疗3个月后,研究组患者的病情稳定、疾病进展发生率分别为6.67%和2.66%,均低于对照组患者的2.66%和18.67%(χ2=10.074 6,P=0.001 5<0.05)。结论转移性乳腺癌HER-2强表达患者在采用曲妥珠单抗及多西他赛治疗基础上联合护理干预措施疗效更显著,可降低不良反应发生率,改善生活质量,促进机体康复,值得临床推广。

Objective To explore the clinical efficacy of docetaxel and herceptin combined with nursing intervention in treating metastat-ic breast cancer HER-2 strong expression. Methods 150 patients with metastatic breast cancer HER-2 strong expression from March 2011 to May 2014 were randomly divided into study group and control group, 75 casesin each group. The control group simply received docetaxel and herceptin therapy, the study group added nursing interventions. Results 3 months after treatment, fever, rash, bone marrow suppression, gastrointestinal discomfort and other adverse reactions in the study group were lower than those in the control group (χ2=7. 292 1, P=0. 006 9 < 0. 05 ); the KPS and QOL scores of the two groups were significantly higher than before treatment, and the study group was significantly higher than the control group( P < 0. 05);the rates of SD and PD cases in the study group were 6. 67%, 2. 66%, which were lower than 2. 66%, 18. 67% of the control group (χ2=10. 074 6, P=0. 001 5 < 0. 05 ) . Conclusion Docetaxel and herceptin combined with nursing interventions in treating patients with metastatic breast cancer HER-2 strong expression can achieve more significant clinical effect, reduce the incidence of adverse reactions, improve the quality of life of patients, promote body recovery, and is worthy of clinical application.